Index- P/E- EPS (ttm)-3.60 Insider Own- Shs Outstand31.02M Perf Week3.20%
Market Cap35.91M Forward P/E- EPS next Y- Insider Trans- Shs Float17.84M Perf Month-12.40%
Income- PEG- EPS next Q- Inst Own10.80% Short Float0.54% Perf Quarter-31.10%
Sales4.18M P/S8.59 EPS this Y43.00% Inst Trans-20.20% Short Ratio0.10 Perf Half Y-53.97%
Book/sh1.32 P/B0.85 EPS next Y- ROA- Target Price- Perf Year-80.35%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.00 - 9.50 Perf YTD-51.91%
Dividend- P/FCF- EPS past 5Y- ROI-131.50% 52W High-88.11% Beta2.12
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low12.99% ATR0.16
Employees181 Current Ratio- Sales Q/Q-50.00% Oper. Margin- RSI (14)41.92 Volatility11.77% 11.55%
OptionableYes Debt/Eq- EPS Q/Q62.90% Profit Margin- Rel Volume0.02 Prev Close1.18
ShortableYes LT Debt/Eq- EarningsApr 28 AMC Payout- Avg Volume951.42K Price1.13
Recom1.70 SMA20-9.29% SMA50-21.12% SMA200-62.84% Volume15,481 Change-4.24%
May-24-22 04:05PM  
May-17-22 04:05PM  
May-13-22 12:00PM  
May-12-22 04:05PM  
Apr-28-22 04:05PM  
Apr-25-22 02:00AM  
Apr-06-22 04:05PM  
Apr-04-22 01:30AM  
Mar-28-22 04:05PM  
Mar-11-22 05:18PM  
Mar-04-22 12:00PM  
Feb-09-22 12:53PM  
Feb-08-22 04:05PM  
Jan-10-22 12:00PM  
Jan-03-22 04:05PM  
Dec-14-21 01:30AM  
Dec-13-21 04:05PM  
Dec-10-21 12:00PM  
Dec-01-21 09:22AM  
Nov-29-21 04:05PM  
Nov-15-21 04:05PM  
Nov-10-21 01:30AM  
Nov-09-21 02:00AM  
Nov-05-21 01:21PM  
Oct-25-21 12:11PM  
Oct-07-21 12:00PM  
Oct-04-21 04:05PM  
Sep-28-21 04:05PM  
Sep-22-21 12:30PM  
Sep-20-21 04:05PM  
Sep-15-21 04:05PM  
Sep-06-21 04:05PM  
Sep-03-21 12:00PM  
Aug-30-21 04:05PM  
Aug-24-21 04:30PM  
Aug-05-21 12:00PM  
Jul-30-21 08:50AM  
Jul-29-21 04:05PM  
Jul-27-21 01:30AM  
Jul-21-21 04:05PM  
Jul-06-21 12:00PM  
Jun-25-21 04:30PM  
Jun-07-21 12:00PM  
May-26-21 04:30PM  
May-25-21 04:00PM  
May-07-21 12:00PM  
May-04-21 04:30PM  
Apr-29-21 02:30AM  
Apr-28-21 07:30PM  
Apr-20-21 01:30AM  
Apr-19-21 01:30AM  
Apr-07-21 04:30PM  
Mar-09-21 04:30PM  
Mar-08-21 04:30PM  
Mar-05-21 12:00PM  
Mar-04-21 04:30PM  
Feb-24-21 04:30PM  
Feb-10-21 04:30PM  
Feb-08-21 01:30AM  
Feb-04-21 01:00PM  
Jan-25-21 04:30PM  
Jan-14-21 04:30PM  
Jan-13-21 08:36AM  
Jan-06-21 04:30PM  
Jan-04-21 02:00AM  
Dec-14-20 04:30PM  
Dec-10-20 04:30PM  
Dec-07-20 02:00AM  
Dec-03-20 04:30PM  
Nov-12-20 04:30PM  
Nov-05-20 04:30PM  
Nov-04-20 12:00PM  
Nov-02-20 03:19AM  
Oct-29-20 05:30PM  
Oct-26-20 05:30PM  
Oct-12-20 05:51AM  
Sep-21-20 04:45PM  
Sep-16-20 04:30PM  
Sep-14-20 04:30PM  
Aug-06-20 12:00PM  
Jul-10-20 12:00PM  
Jun-26-20 04:30PM  
Jun-25-20 08:26AM  
Jun-09-20 12:00PM  
Jun-02-20 04:30PM  
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.